Vesuvius India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 6:16 pm

Quick Insight

Vesuvius India Ltd, with a share price of ₹535 and a market cap of 10,831 Cr., is trading at a P/E of 42.5, indicating a premium valuation. The company boasts a healthy ROE of 19.3% and ROCE of 25.5%, showcasing efficient capital utilization. With an OPM of 17% and a Net Profit of 265 Cr., Vesuvius demonstrates strong operational performance. Additionally, the company's low borrowings of ₹13 Cr. and high ICR of 335.48x reflect a robust financial position. Despite a high P/BV of 6.46x, the stock may be considered overvalued. Investors should closely monitor operational efficiency and growth prospects to make informed investment decisions.

Competitors of Vesuvius India Ltd

All Competitor Stocks of Vesuvius India Ltd

Quarterly Result

Last Updated: July 16, 2025, 4:15 pm

Below is a detailed analysis of the quarterly data for Vesuvius India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 482.00 Cr.. The value appears to be declining and may need further review. It has decreased from 509.00 Cr. (Dec 2024) to 482.00 Cr., marking a decrease of 27.00 Cr..
• For Expenses, as of Mar 2025, the value is 399.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 427.00 Cr. (Dec 2024) to 399.00 Cr., marking a decrease of 28.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 83.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Dec 2024) to 83.00 Cr., marking an increase of 1.00 Cr..
• For OPM %, as of Mar 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Dec 2024) to 17.00%, marking an increase of 1.00%.
• For Other Income, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Dec 2024) to 10.00 Cr., marking an increase of 3.00 Cr..
• For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
• For Depreciation, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 13.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 80.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Dec 2024) to 80.00 Cr., marking an increase of 4.00 Cr..
• For Tax %, as of Mar 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Dec 2024) to 26.00%, marking an increase of 4.00%.
• For Net Profit, as of Mar 2025, the value is 59.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Dec 2024) to 59.00 Cr., marking a decrease of 1.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 2.92. The value appears to be declining and may need further review. It has decreased from 2.95 (Dec 2024) to 2.92, marking a decrease of 0.03.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:30 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:06 pm

Below is a detailed analysis of the balance sheet data for Vesuvius India Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

• For Equity Capital, as of Dec 2024, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 20.00 Cr..
• For Reserves, as of Dec 2024, the value is 1,411.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,173.00 Cr. (Dec 2023) to 1,411.00 Cr., marking an increase of 238.00 Cr..
• For Borrowings, as of Dec 2024, the value is 13.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Dec 2023) which recorded 13.00 Cr..
• For Other Liabilities, as of Dec 2024, the value is 402.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 382.00 Cr. (Dec 2023) to 402.00 Cr., marking an increase of 20.00 Cr..
• For Total Liabilities, as of Dec 2024, the value is 1,847.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,589.00 Cr. (Dec 2023) to 1,847.00 Cr., marking an increase of 258.00 Cr..
• For Fixed Assets, as of Dec 2024, the value is 434.00 Cr.. The value appears strong and on an upward trend. It has increased from 316.00 Cr. (Dec 2023) to 434.00 Cr., marking an increase of 118.00 Cr..
• For CWIP, as of Dec 2024, the value is 196.00 Cr.. The value appears strong and on an upward trend. It has increased from 86.00 Cr. (Dec 2023) to 196.00 Cr., marking an increase of 110.00 Cr..
• For Investments, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 0.00 Cr..
• For Other Assets, as of Dec 2024, the value is 1,217.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,187.00 Cr. (Dec 2023) to 1,217.00 Cr., marking an increase of 30.00 Cr..
• For Total Assets, as of Dec 2024, the value is 1,847.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,589.00 Cr. (Dec 2023) to 1,847.00 Cr., marking an increase of 258.00 Cr..

Notably, the Reserves (1,411.00 Cr.) exceed the Borrowings (13.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Vesuvius India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Dec 24, the value is 130.33. This value is within the healthy range. It has increased from 104.92 (Dec 23) to 130.33, marking an increase of 25.41.
• For Diluted EPS (Rs.), as of Dec 24, the value is 130.33. This value is within the healthy range. It has increased from 104.92 (Dec 23) to 130.33, marking an increase of 25.41.
• For Cash EPS (Rs.), as of Dec 24, the value is 152.89. This value is within the healthy range. It has increased from 122.59 (Dec 23) to 152.89, marking an increase of 30.30.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 704.92. It has increased from 587.95 (Dec 23) to 704.92, marking an increase of 116.97.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 704.92. It has increased from 587.95 (Dec 23) to 704.92, marking an increase of 116.97.
• For Dividend / Share (Rs.), as of Dec 24, the value is 14.50. This value exceeds the healthy maximum of 3. It has increased from 12.75 (Dec 23) to 14.50, marking an increase of 1.75.
• For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 920.48. It has increased from 789.72 (Dec 23) to 920.48, marking an increase of 130.76.
• For PBDIT / Share (Rs.), as of Dec 24, the value is 195.01. This value is within the healthy range. It has increased from 158.50 (Dec 23) to 195.01, marking an increase of 36.51.
• For PBIT / Share (Rs.), as of Dec 24, the value is 172.42. This value is within the healthy range. It has increased from 140.80 (Dec 23) to 172.42, marking an increase of 31.62.
• For PBT / Share (Rs.), as of Dec 24, the value is 171.84. This value is within the healthy range. It has increased from 140.59 (Dec 23) to 171.84, marking an increase of 31.25.
• For Net Profit / Share (Rs.), as of Dec 24, the value is 130.31. This value is within the healthy range. It has increased from 104.90 (Dec 23) to 130.31, marking an increase of 25.41.
• For PBDIT Margin (%), as of Dec 24, the value is 21.18. This value is within the healthy range. It has increased from 20.07 (Dec 23) to 21.18, marking an increase of 1.11.
• For PBIT Margin (%), as of Dec 24, the value is 18.73. This value is within the healthy range. It has increased from 17.82 (Dec 23) to 18.73, marking an increase of 0.91.
• For PBT Margin (%), as of Dec 24, the value is 18.66. This value is within the healthy range. It has increased from 17.80 (Dec 23) to 18.66, marking an increase of 0.86.
• For Net Profit Margin (%), as of Dec 24, the value is 14.15. This value exceeds the healthy maximum of 10. It has increased from 13.28 (Dec 23) to 14.15, marking an increase of 0.87.
• For Return on Networth / Equity (%), as of Dec 24, the value is 18.48. This value is within the healthy range. It has increased from 17.84 (Dec 23) to 18.48, marking an increase of 0.64.
• For Return on Capital Employeed (%), as of Dec 24, the value is 23.79. This value is within the healthy range. It has increased from 23.22 (Dec 23) to 23.79, marking an increase of 0.57.
• For Return On Assets (%), as of Dec 24, the value is 14.32. This value is within the healthy range. It has increased from 13.40 (Dec 23) to 14.32, marking an increase of 0.92.
• For Asset Turnover Ratio (%), as of Dec 24, the value is 1.09. It has decreased from 1.10 (Dec 23) to 1.09, marking a decrease of 0.01.
• For Current Ratio (X), as of Dec 24, the value is 3.12. This value exceeds the healthy maximum of 3. It has increased from 3.10 (Dec 23) to 3.12, marking an increase of 0.02.
• For Quick Ratio (X), as of Dec 24, the value is 2.47. This value exceeds the healthy maximum of 2. It has increased from 2.38 (Dec 23) to 2.47, marking an increase of 0.09.
• For Inventory Turnover Ratio (X), as of Dec 24, the value is 2.59. This value is below the healthy minimum of 4. It has decreased from 2.64 (Dec 23) to 2.59, marking a decrease of 0.05.
• For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 9.78. This value is below the healthy minimum of 20. It has increased from 7.86 (Dec 23) to 9.78, marking an increase of 1.92.
• For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 8.33. This value is below the healthy minimum of 20. It has increased from 6.72 (Dec 23) to 8.33, marking an increase of 1.61.
• For Earning Retention Ratio (%), as of Dec 24, the value is 90.22. This value exceeds the healthy maximum of 70. It has decreased from 92.14 (Dec 23) to 90.22, marking a decrease of 1.92.
• For Cash Earning Retention Ratio (%), as of Dec 24, the value is 91.67. This value exceeds the healthy maximum of 70. It has decreased from 93.28 (Dec 23) to 91.67, marking a decrease of 1.61.
• For Interest Coverage Ratio (X), as of Dec 24, the value is 335.48. This value is within the healthy range. It has decreased from 748.26 (Dec 23) to 335.48, marking a decrease of 412.78.
• For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 225.17. This value is within the healthy range. It has decreased from 496.21 (Dec 23) to 225.17, marking a decrease of 271.04.
• For Enterprise Value (Cr.), as of Dec 24, the value is 8,763.00. It has increased from 6,817.43 (Dec 23) to 8,763.00, marking an increase of 1,945.57.
• For EV / Net Operating Revenue (X), as of Dec 24, the value is 4.69. This value exceeds the healthy maximum of 3. It has increased from 4.25 (Dec 23) to 4.69, marking an increase of 0.44.
• For EV / EBITDA (X), as of Dec 24, the value is 22.14. This value exceeds the healthy maximum of 15. It has increased from 21.19 (Dec 23) to 22.14, marking an increase of 0.95.
• For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 4.95. This value exceeds the healthy maximum of 3. It has increased from 4.54 (Dec 23) to 4.95, marking an increase of 0.41.
• For Retention Ratios (%), as of Dec 24, the value is 90.21. This value exceeds the healthy maximum of 70. It has decreased from 92.13 (Dec 23) to 90.21, marking a decrease of 1.92.
• For Price / BV (X), as of Dec 24, the value is 6.46. This value exceeds the healthy maximum of 3. It has increased from 6.10 (Dec 23) to 6.46, marking an increase of 0.36.
• For Price / Net Operating Revenue (X), as of Dec 24, the value is 4.95. This value exceeds the healthy maximum of 3. It has increased from 4.54 (Dec 23) to 4.95, marking an increase of 0.41.
• For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Dec 23) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness